Published: 22 January 2015
Author(s): Olga Vriz, Rosalba Minisini, Maurizio Ruscio, Paolo Calabro, Eduardo Bossone
Section: Letter to the Editor

ST2 is a receptor of the interleukin (IL)-1 family, a biomarker of inflammatory and cardiovascular disease with transmembrane (ST2L) and soluble (sST2) isoforms, released by cardiomyocytes in response to mechanical wall strain [1]. Serum sST2 predicts outcome after myocardial infarction (MI) or chronic heart failure [2,3]. Tako-tsubo cardiomyopathy (TTC) is an acute cardiac condition characterized by transient myocardial dysfunction, almost normal coronary arteries [4], long-term favorable prognosis and few in-hospital complications [5].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.